Masatomo Miura

TL;DR: Ass associations between IM trough concentration, clinical response and 11 single-nucleotide polymorphisms in genes involved in IM pharmacokinetics were investigated and data indicate that plasma IM concentration monitoring and prospective ABCG2 421C>A genotyping may improve the efficacy of IM therapy, particularly among Asian CML patients.

TL;DR: The dose-adjusted area under the cuve (AUC)6–12 of MPA, an estimate of enterohepatic recirculation, was greater in SLCO1B3 T334G GG (or G699A AA) carriers than in TT carriers (orG699A GG) (40 vs. 25 ng·h/mL per milligram, respectively, P = 0.0497).

TL;DR: Metabolism studies of these compounds revealed that compound 4 is readily metabolized in mouse liver, Accordingly, the dose of 4 must be higher than that of 3 to attain blood levels sufficient for a favorable therapeutic effect.

TL;DR: MPA exposure should be measured and doses should be adjusted accordingly to achieve optimal clinical outcomes and limited sampling strategies to estimate MPA exposure from EC-MPS have not yet been well developed and fully evaluated, nor have accurate Bayesian estimators been reported.

TL;DR: Renal transplant recipients who were CYP3A5*1 carriers required a higher dose of tacrolimus than CYP5*3/*3, indicating a significantly lower dose-adjusted AUC0-12 of tacolimus, and the MDR1 C3435T polymorphism was not an important factor in tac rolimus pharmacokinetics.